12:00 AM
 | 
Jun 25, 2012
 |  BC Week In Review  |  Company News  |  Other News

Emergent BioSolutions, Kalon Biotherapeutics, Lonza, GlaxoSmithKline, Novartis, Texas A&M University System infectious news

HHS's Biomedical Advanced Research and Development Authority (BARDA) will invest about $400 million to establish three private-public consortia to develop and manufacture medical countermeasures. Each consortium will retrofit existing facilities or build new facilities that will use cell and recombinant-based vaccine technologies to develop countermeasures for pandemic influenza and other threats. HHS expects the facilities to become operational in 2014-15 with the combined capability to produce a quarter of...

Read the full 323 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >